ProBio Unveils Innovative Manufacturing Hub for Gene Therapy
ProBio, a leading global contract development and manufacturing organization (CDMO), has officially inaugurated its Cell and Gene Therapy Center of Excellence located at the Princeton West Innovation Campus in Hopewell, New Jersey. This impressive 128,000 square foot facility is tailored specifically for the production of high-quality plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms. The establishment of this facility underscores ProBio's commitment to pushing the boundaries of cell and gene therapy.
The grand opening, held on June 27, 2025, was marked by a ribbon-cutting ceremony featuring prominent figures including ProBio's CEO, Allen Guo, and other notable leaders such as Courtney Peters-Manning, Mayor of Hopewell Township, and representatives from the New Jersey Economic Development Authority (NJEDA). Michael Vreeland, who serves as the site head, emphasized the facility's potential to foster innovation and growth within New Jersey’s biomanufacturing sector.
One of the defining moments of the event was a heartfelt keynote address by Donavon Decker, the first recipient of gene therapy for muscular dystrophy. His inspiring story highlighted the transformative impact that advanced therapies can have on patients, reinforcing the importance of ProBio’s mission and operations. "This is not just a new facility. It is a beacon of hope for patients waiting for cures," said Allen Guo, underlining the facility's role in accelerating the delivery of life-changing treatments.
ProBio’s new site is equipped to handle the most rigorous Good Manufacturing Practice (GMP) standards, positioning it as a pivotal player in clinical-stage development and process scalability for cell and gene therapeutic programs. The facility aims to create over 110 skilled jobs, further solidifying New Jersey's status as a hub for advanced biopharmaceutical production.
As part of the opening celebration, guests were given guided tours of the advanced GMP suites and production lines. This engagement allowed stakeholders, including industry peers and academic partners, to witness firsthand the innovative capabilities of the facility, as well as its strategic role in supporting clinical trial registrations and expediting patient access to groundbreaking treatments.
Strategically situated within New Jersey’s innovation corridor, ProBio’s Hopewell location serves as the North American hub for the company, with plans to expand its capabilities significantly. By Q3 of 2025, the production of GMP AAV will commence, followed by GMP LVV services expected to kick off in Q1 of 2026. This expansion will support a wider variety of therapeutic candidates, streamlining the journey from early-stage proof-of-concept to clinical readiness all under one roof.
This opening not only represents a significant milestone in ProBio’s global transition but also highlights the company’s dedication to providing high-quality, responsive manufacturing solutions to biopharma innovators. By fostering a collaborative, risk-sharing environment, ProBio is at the forefront of simplifying the complexities involved in drug development.
To learn more about ProBio and its full suite of development and manufacturing services, interested parties can visit their website at
ProBio CDMO. This facility is more than just a production site; it is a step forward in redefining the future of medicine and patient care across the globe.